Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHT-COG: Mazdutide in Type 2 Diabetes and Early-Stage Cognitive Impairment
NCT07083154Phase 3Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Sep 2025
- Primary completion
- Aug 2029
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of mazdutide in Mild Cognitive Impairment (MCI), sponsored by Nanjing Drum-Tower Hospital. Started Sep 2025; status: recruiting.
02
Drugs
mazdutide
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07083154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07083154.